Replies to post #15659 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>“LEO has confirmed that there are no safety or efficacy issues with the ATryn product, either commercially or in the phase II DIC clinical study.”<

This excerpt does not pass the smell test, IMO. I think it’s a near certainty that Leo saw something in the phase-2 data that was not to its liking.

[MadCityCyclone]

gs:

your highlighting pen should have bolded the most telling and reocurring words of the whole gtcb story:

slower than planned